<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Thu, 20 Jun 2024 06:13:03 +0000</lastbuilddate>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897683/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2714. doi: 10.1016/j.jacc.2024.05.010.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897683/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897683</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.010>10.1016/j.jacc.2024.05.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897683</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:38897683</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.010</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897682/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2714. doi: 10.1016/j.jacc.2024.05.033.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897682/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897682</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.033>10.1016/j.jacc.2024.05.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897682</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:38897682</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.033</dc:identifier>
</item>
<item>
<title>Early Renal Dysfunction in Middle-Aged Adults Predicts Fatal and Nonfatal Cardiovascular Events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897681/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2711-2713. doi: 10.1016/j.jacc.2024.04.029.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897681/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897681</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.029>10.1016/j.jacc.2024.04.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897681</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Yap-Hang Chan</dc:creator>
<dc:creator>Jie V Zhao</dc:creator>
<dc:creator>Shiu-Lun Au Yeung</dc:creator>
<dc:creator>Yuen-Kwun Wong</dc:creator>
<dc:creator>Ka-Wing Au</dc:creator>
<dc:creator>Aimin Xu</dc:creator>
<dc:creator>Tai-Hing Lam</dc:creator>
<dc:creator>Bernard M Y Cheung</dc:creator>
<dc:creator>Karen Siu-Ling Lam</dc:creator>
<dc:creator>Hung-Fat Tse</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Early Renal Dysfunction in Middle-Aged Adults Predicts Fatal and Nonfatal Cardiovascular Events</dc:title>
<dc:identifier>pmid:38897681</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.029</dc:identifier>
</item>
<item>
<title>A Time for Reflection: 10 Years With JACC</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897680/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2708-2710. doi: 10.1016/j.jacc.2024.05.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897680/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897680</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.020>10.1016/j.jacc.2024.05.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897680</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Valentin Fuster</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Time for Reflection: 10 Years With JACC</dc:title>
<dc:identifier>pmid:38897680</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.020</dc:identifier>
</item>
<item>
<title>Addressing the Global Burden of Cardiovascular Disease in Women: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897679/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>Cardiovascular diseases (CVDs) are responsible for approximately 35% of all deaths in women. In 2019, the global age-standardized CVD prevalence and mortality of women were 6,403 per 100,000 and 204 per 100,000, respectively. Although the age- and population-adjusted prevalence has decreased globally, opposite trends are evident in regions of socioeconomic deprivation. Cardiovascular health and outcomes are influenced by regional socioeconomic, environmental, and community factors, in addition...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2690-2707. doi: 10.1016/j.jacc.2024.04.028.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiovascular diseases (CVDs) are responsible for approximately 35% of all deaths in women. In 2019, the global age-standardized CVD prevalence and mortality of women were 6,403 per 100,000 and 204 per 100,000, respectively. Although the age- and population-adjusted prevalence has decreased globally, opposite trends are evident in regions of socioeconomic deprivation. Cardiovascular health and outcomes are influenced by regional socioeconomic, environmental, and community factors, in addition to health care system and individual factors. Cardiovascular care in women is commonly plagued by delayed diagnoses, undertreatment, and knowledge gaps, particularly in women-specific or women-predominant conditions. In this paper, we describe the global epidemiology of CVD and highlight multilevel determinants of cardiometabolic health. We review knowledge and health care gaps that serve as barriers to improving CVD outcomes in women. Finally, we present national, community, health care system, and research strategies to comprehensively address cardiometabolic risk and improve outcomes in women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897679/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897679</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.028>10.1016/j.jacc.2024.04.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897679</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Dominique Vervoort</dc:creator>
<dc:creator>Ruoting Wang</dc:creator>
<dc:creator>Guowei Li</dc:creator>
<dc:creator>Lynaea Filbey</dc:creator>
<dc:creator>Omosivie Maduka</dc:creator>
<dc:creator>LaPrincess C Brewer</dc:creator>
<dc:creator>Mamas A Mamas</dc:creator>
<dc:creator>Maria Cecilia Bahit</dc:creator>
<dc:creator>Sofia B Ahmed</dc:creator>
<dc:creator>Harriette G C Van Spall</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Addressing the Global Burden of Cardiovascular Disease in Women: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38897679</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.028</dc:identifier>
</item>
<item>
<title>Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897678/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>Iron deficiency and heart failure frequently co-occur, sparking clinical research into the role of iron repletion in this condition over the last 20 years. Although early nonrandomized studies and subsequent moderate-sized randomized controlled trials showed an improvement in symptoms and functional metrics with the use of intravenous iron, 3 recent larger trials powered to detect a difference in hard cardiovascular outcomes failed to meet their primary endpoints. Additionally, there are...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2674-2689. doi: 10.1016/j.jacc.2024.03.431.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Iron deficiency and heart failure frequently co-occur, sparking clinical research into the role of iron repletion in this condition over the last 20 years. Although early nonrandomized studies and subsequent moderate-sized randomized controlled trials showed an improvement in symptoms and functional metrics with the use of intravenous iron, 3 recent larger trials powered to detect a difference in hard cardiovascular outcomes failed to meet their primary endpoints. Additionally, there are potential concerns related to side effects from intravenous iron, both in the short and long term. This review discusses the basics of iron biology and regulation, the diagnostic criteria for iron deficiency and the clinical evidence for intravenous iron in heart failure, safety concerns, and alternative therapies. We also make practical suggestions for the management of patients with iron deficiency and heart failure and outline key areas in need of future research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897678/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897678</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.431>10.1016/j.jacc.2024.03.431</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897678</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Baljash Cheema</dc:creator>
<dc:creator>Anuj Chokshi</dc:creator>
<dc:creator>Olusola Orimoloye</dc:creator>
<dc:creator>Hossein Ardehali</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38897678</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.431</dc:identifier>
</item>
<item>
<title>Team-Based Care to Overcome Therapeutic Inertia in PAD: A Step in the Right Direction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897677/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2671-2673. doi: 10.1016/j.jacc.2024.04.033.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897677/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897677</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.033>10.1016/j.jacc.2024.04.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897677</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Dave L Dixon</dc:creator>
<dc:creator>Anurag Mehta</dc:creator>
<dc:creator>Gregory Moneta</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Team-Based Care to Overcome Therapeutic Inertia in PAD: A Step in the Right Direction</dc:title>
<dc:identifier>pmid:38897677</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.033</dc:identifier>
</item>
<item>
<title>Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897676/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: OPTIMIZE PAD-1 showed that an interprofessional, algorithm-based program can achieve rapid LDL-C lowering in vascular patients using available insurance and therapies, and LDL-C targets can be met in most patients if enabled by optimized systems of care.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2658-2670. doi: 10.1016/j.jacc.2024.04.034.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Underutilization of therapies to reduce ischemic risk in peripheral artery disease (PAD) persists.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose was to conduct an implementation trial of lipid management in vascular disease.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The OPTIMIZE PAD-1 (Implementation of Vascular Care Team to Improve Medical Management of PAD Patients) trial randomized patients with peripheral artery disease with low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL to management via a vascular care team including a clinical pharmacist and an algorithm of intensive lipid management to achieve goal LDL-C in 1 step vs usual care plus provider education. Medications were obtained using commercial insurance. The primary endpoint was percent change in LDL-C at 12 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 166 enrolled patients, 74.2% did not have an LDL-C level at goal. Among 114 randomized patients (mean age 66 years, 36.0% women, and 15.8% Black), 50.9% received high-intensity statin, and 7.9% received ezetimibe at baseline. The mean 12-month LDL-C change was -49.1% (95% CI: -58.7% to -39.5%) with vascular care team management and -5.4% (95% CI: -15.3% to 4.6%) with usual care; the between-group least-squares mean difference was -43.7% (95% CI: -57.6% to -29.9%; P &lt; 0.0001). Mean LDL-C was reduced in vascular care team patients from 100.6 mg/dL at baseline to 54.8 and 50.1 mg/dL by week 4 and month 12, respectively. At 12 months, vascular care team patients were >;3 times as likely to achieve LDL-C &lt;70 mg/dL and 8 times as likely to achieve LDL-C &lt;55 mg/dL (P &lt; 0.0001) than usual care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: OPTIMIZE PAD-1 showed that an interprofessional, algorithm-based program can achieve rapid LDL-C lowering in vascular patients using available insurance and therapies, and LDL-C targets can be met in most patients if enabled by optimized systems of care.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897676/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897676</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.034>10.1016/j.jacc.2024.04.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897676</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Connie N Hess</dc:creator>
<dc:creator>Ashley Daffron</dc:creator>
<dc:creator>Mark R Nehler</dc:creator>
<dc:creator>Justin T Morrison</dc:creator>
<dc:creator>Cullen E Buchanan</dc:creator>
<dc:creator>Michael Szarek</dc:creator>
<dc:creator>Victoria E Anderson</dc:creator>
<dc:creator>Christopher P Cannon</dc:creator>
<dc:creator>Judith Hsia</dc:creator>
<dc:creator>Joseph J Saseen</dc:creator>
<dc:creator>Marc P Bonaca</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease</dc:title>
<dc:identifier>pmid:38897676</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.034</dc:identifier>
</item>
<item>
<title>Fueling the Fire: Autoimmunity and Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897675/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2655-2657. doi: 10.1016/j.jacc.2024.04.031.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897675/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897675</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.031>10.1016/j.jacc.2024.04.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897675</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Brittany N Weber</dc:creator>
<dc:creator>Ron Blankstein</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Fueling the Fire: Autoimmunity and Atherosclerosis</dc:title>
<dc:identifier>pmid:38897675</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.031</dc:identifier>
</item>
<item>
<title>Association of Autoimmune Diseases With Coronary Atherosclerosis Severity and Ischemic Events</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Autoimmune diseases were independently associated with higher burden of coronary atherosclerosis and higher risk for future ASCVD events, with risk accentuated by traditional cardiovascular risk factors. These findings suggest that autoimmune diseases increase risk through accelerated atherogenesis and that cardiovascular risk factor control is key for improving prognosis in patients with autoimmune diseases.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2643-2654. doi: 10.1016/j.jacc.2024.04.030.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Some autoimmune diseases carry elevated risk for atherosclerotic cardiovascular disease (ASCVD), yet the underlying mechanism and the influence of traditional risk factors remain unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine whether autoimmune diseases independently correlate with coronary atherosclerosis and ASCVD risk and whether traditional cardiovascular risk factors modulate the risk.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The study included 85,512 patients from the Western Denmark Heart Registry undergoing coronary computed tomography angiography. A diagnosis of 1 of 18 autoimmune diseases was assessed. Adjusted OR (aOR) for any plaque, any coronary artery calcification (CAC), CAC of >;90th percentile, and obstructive coronary artery disease as well as adjusted HR (aHR) for ASCVD were calculated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During 5.3 years (Q1-Q3: 2.8-8.2 years) of follow-up, 3,832 ASCVD events occurred. A total of 4,064 patients had a diagnosis of autoimmune disease, which was associated with both presence of any plaque (aOR: 1.29; 95% CI: 1.20-1.40), any CAC (aOR: 1.28; 95% CI: 1.19-1.37), and severe CAC of >;90th percentile (aOR: 1.53; 95% CI: 1.39-1.68), but not with having obstructive coronary artery disease (aOR: 1.04; 95% CI: 0.91-1.17). Patients with autoimmune diseases had a 46% higher risk (aHR: 1.46; 95% CI: 1.29-1.65) for ASCVD. Traditional cardiovascular risk factors were strongly associated with future ASCVD events, and a favorable cardiovascular risk factor profile in autoimmune patients was associated with ∼54% lower risk compared to patients with presence of risk factors (aHR: 0.46; 95% CI: 0.27-0.81).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Autoimmune diseases were independently associated with higher burden of coronary atherosclerosis and higher risk for future ASCVD events, with risk accentuated by traditional cardiovascular risk factors. These findings suggest that autoimmune diseases increase risk through accelerated atherogenesis and that cardiovascular risk factor control is key for improving prognosis in patients with autoimmune diseases.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897674</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.030>10.1016/j.jacc.2024.04.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897674</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Martin Bødtker Mortensen</dc:creator>
<dc:creator>Jesper Møller Jensen</dc:creator>
<dc:creator>Niels Peter Rønnow Sand</dc:creator>
<dc:creator>Kristian Kragholm</dc:creator>
<dc:creator>Michael J Blaha</dc:creator>
<dc:creator>Erik Lerkevang Grove</dc:creator>
<dc:creator>Henrik Toft Sørensen</dc:creator>
<dc:creator>Kevin Olesen</dc:creator>
<dc:creator>Michael Maeng</dc:creator>
<dc:creator>Brian Løgstrup</dc:creator>
<dc:creator>Martin Busk</dc:creator>
<dc:creator>Ellen Margrethe Hauge</dc:creator>
<dc:creator>Ann Marie Navar</dc:creator>
<dc:creator>Hans Erik Bøtker</dc:creator>
<dc:creator>Bjarne Linde Nørgaard</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Association of Autoimmune Diseases With Coronary Atherosclerosis Severity and Ischemic Events</dc:title>
<dc:identifier>pmid:38897674</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.030</dc:identifier>
</item>
<item>
<title>Antiplatelet Therapy, Pretreatment, and Primary PCI: Every Minute Counts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897673/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2640-2642. doi: 10.1016/j.jacc.2024.04.035.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897673/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897673</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.035>10.1016/j.jacc.2024.04.035</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897673</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Johanne Silvain</dc:creator>
<dc:creator>Gilles Montalescot</dc:creator>
<dc:creator>Paul Guedeney</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Antiplatelet Therapy, Pretreatment, and Primary PCI: Every Minute Counts</dc:title>
<dc:identifier>pmid:38897673</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.035</dc:identifier>
</item>
<item>
<title>Timing of P2Y&lt;sub>;12&lt;/sub>; Inhibitor Administration in Patients With STEMI Undergoing Primary PCI</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897672/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In contemporary patients with STEMI transferred for primary PCI, pretreatment with P2Y(12) inhibitors was associated with a significant time-dependent reduction of 30-day MACE without increasing bleeding risk.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2629-2639. doi: 10.1016/j.jacc.2024.04.036.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The optimal timing of P2Y<sub>12</sub> inhibitor administration in patients with ST-segment elevation myocardial infarction (STEMI) has not been completely elucidating.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This analysis from a prospective multicenter registry sought to assess the safety and effectiveness of P2Y<sub>12</sub> inhibitor pretreatment in patients transferred for primary percutaneous coronary intervention (PCI) within a regional STEMI network.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Pretreatment was defined as P2Y<sub>12</sub> inhibitor administration before coronary angiography. Endpoints were major adverse cardiac events (MACE), major bleeding, and net adverse clinical events, a composite of MACE or major bleeding, within 30 days of index admission. Association of P2Y<sub>12</sub> inhibitor pretreatment with outcomes was modeled using doubly robust weighted estimators based on propensity score analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 1,624 patients included, 1,033 received P2Y<sub>12</sub> inhibitors before angiography and 591 in the catheterization laboratory (cath lab). The non-pretreated cohort more often had history of coronary artery disease and were more likely to receive antiplatelet therapy before the index admission. After adjustment for confounding and dependent censoring, pretreatment with P2Y<sub>12</sub> inhibitors predicted lower risk of MACE (adjusted HR: 0.53; 95% CI: 0.37-0.76), without increasing bleeding risk (adjusted HR: 0.62; 95% CI: 0.36-1.05), resulting in superior net clinical benefit (adjusted HR: 0.47; 95% CI: 0.26-0.86) compared with in-cath lab administration of P2Y<sub>12</sub> inhibitors. There was a significant treatment-by-time interaction for MACE risk, whereby the observed benefits of pretreatment only became apparent when time between P2Y<sub>12</sub> inhibitor administration and PCI was longer than 80 minutes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In contemporary patients with STEMI transferred for primary PCI, pretreatment with P2Y<sub>12</sub> inhibitors was associated with a significant time-dependent reduction of 30-day MACE without increasing bleeding risk.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897672/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897672</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.036>10.1016/j.jacc.2024.04.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897672</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Manuel Almendro-Delia</dc:creator>
<dc:creator>Begoña Hernández-Meneses</dc:creator>
<dc:creator>Gloria Padilla-Rodríguez</dc:creator>
<dc:creator>Emilia Blanco-Ponce</dc:creator>
<dc:creator>Jose Andres Arboleda-Sánchez</dc:creator>
<dc:creator>Juan Carlos Rodríguez-Yáñez</dc:creator>
<dc:creator>José Manuel Soto-Blanco</dc:creator>
<dc:creator>Isabel Fernández-García</dc:creator>
<dc:creator>José M Castillo-Caballero</dc:creator>
<dc:creator>Juan C García-Rubira</dc:creator>
<dc:creator>Rafael Hidalgo-Urbano</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Timing of P2Y&lt;sub>;12&lt;/sub>; Inhibitor Administration in Patients With STEMI Undergoing Primary PCI</dc:title>
<dc:identifier>pmid:38897672</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.036</dc:identifier>
</item>
<item>
<title>Evaluating Long-Term Care After ST-Segment Elevation Myocardial Infarction With a Population-Based Comprehensive Medical Record</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897671/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2626-2628. doi: 10.1016/j.jacc.2024.04.026.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897671/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897671</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.026>10.1016/j.jacc.2024.04.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897671</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Myron L Weisfeldt</dc:creator>
<dc:creator>Stephen D Sisson</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Evaluating Long-Term Care After ST-Segment Elevation Myocardial Infarction With a Population-Based Comprehensive Medical Record</dc:title>
<dc:identifier>pmid:38897671</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.026</dc:identifier>
</item>
<item>
<title>10-Year Mortality After ST-Segment Elevation Myocardial Infarction Compared to the General Population</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In primary PCI-treated STEMI patients with high use of guideline-recommended therapy, patients surviving the first 90 days had 10-year mortality that was only 2% higher than that of a matched general population.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Jun 25;83(25):2615-2625. doi: 10.1016/j.jacc.2024.04.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: ST-segment elevation myocardial infarction (STEMI) is associated with high early mortality. However, it remains unclear if patients surviving the early phase have long-term excess mortality.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to assess excess mortality in STEMI patients treated with primary percutaneous coronary intervention (PCI) compared with an age- and- sex-matched general population at landmark periods 0 to 30 days, 31 to 90 days, and 91 days to 10 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using the Western Denmark Heart Registry, we identified first-time PCI-treated patients who had primary PCI for STEMI from January 2003 to October 2018. Each patient was matched by age and sex to 5 individuals from the general population.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We included 18,818 patients with first-time STEMI and 94,090 individuals from the general population. Baseline comorbidity burden was similar in STEMI patients and matched individuals. Compared with the matched individuals, STEMI was associated with a 5.9% excess mortality from 0 to 30 days (6.0% vs 0.2%; HR: 36.44; 95% CI: 30.86-43.04). An excess mortality remained present from 31 to 90 days (0.9% vs 0.4%; HR: 2.43; 95% CI: 2.02-2.93). However, in 90-day STEMI survivors, the absolute excess mortality was only 2.1 percentage points at 10-year follow-up (26.5% vs 24.5%; HR: 1.04; 95% CI: 1.01-1.08). Use of secondary preventive medications such as statins, antiplatelet therapy, and beta-blockers was very high in STEMI patients throughout 10-year follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In primary PCI-treated STEMI patients with high use of guideline-recommended therapy, patients surviving the first 90 days had 10-year mortality that was only 2% higher than that of a matched general population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897670</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.025>10.1016/j.jacc.2024.04.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897670</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Pernille Gro Thrane</dc:creator>
<dc:creator>Kevin Kris Warnakula Olesen</dc:creator>
<dc:creator>Troels Thim</dc:creator>
<dc:creator>Christine Gyldenkerne</dc:creator>
<dc:creator>Malene Kærslund Hansen</dc:creator>
<dc:creator>Nina Stødkilde-Jørgensen</dc:creator>
<dc:creator>Lars Jakobsen</dc:creator>
<dc:creator>Martin Bødtker Mortensen</dc:creator>
<dc:creator>Steen Dalby Kristensen</dc:creator>
<dc:creator>Michael Maeng</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>10-Year Mortality After ST-Segment Elevation Myocardial Infarction Compared to the General Population</dc:title>
<dc:identifier>pmid:38897670</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.025</dc:identifier>
</item>
<item>
<title>Therapeutic potential of co-signaling receptor modulation in hepatitis B</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897196/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>Reversing CD8^(+) T cell dysfunction is crucial in treating chronic hepatitis B virus (HBV) infection, yet specific molecular targets remain unclear. Our study analyzed co-signaling receptors during hepatocellular priming and traced the trajectory and fate of dysfunctional HBV-specific CD8^(+) T cells. Early on, these cells upregulate PD-1, CTLA-4, LAG-3, OX40, 4-1BB, and ICOS. While blocking co-inhibitory receptors had minimal effect, activating 4-1BB and OX40 converted them into antiviral...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 14:S0092-8674(24)00582-8. doi: 10.1016/j.cell.2024.05.038. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Reversing CD8<sup>+</sup> T cell dysfunction is crucial in treating chronic hepatitis B virus (HBV) infection, yet specific molecular targets remain unclear. Our study analyzed co-signaling receptors during hepatocellular priming and traced the trajectory and fate of dysfunctional HBV-specific CD8<sup>+</sup> T cells. Early on, these cells upregulate PD-1, CTLA-4, LAG-3, OX40, 4-1BB, and ICOS. While blocking co-inhibitory receptors had minimal effect, activating 4-1BB and OX40 converted them into antiviral effectors. Prolonged stimulation led to a self-renewing, long-lived, heterogeneous population with a unique transcriptional profile. This includes dysfunctional progenitor/stem-like (T<sub>SL</sub>) cells and two distinct dysfunctional tissue-resident memory (T<sub>RM</sub>) populations. While 4-1BB expression is ubiquitously maintained, OX40 expression is limited to T<sub>SL</sub>. In chronic settings, only 4-1BB stimulation conferred antiviral activity. In HBeAg<sup>+</sup> chronic patients, 4-1BB activation showed the highest potential to rejuvenate dysfunctional CD8<sup>+</sup> T cells. Targeting all dysfunctional T cells, rather than only stem-like precursors, holds promise for treating chronic HBV infection.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897196/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897196</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.038>10.1016/j.cell.2024.05.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897196</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Francesco Andreata</dc:creator>
<dc:creator>Chiara Laura</dc:creator>
<dc:creator>Micol Ravà</dc:creator>
<dc:creator>Caroline C Krueger</dc:creator>
<dc:creator>Xenia Ficht</dc:creator>
<dc:creator>Keigo Kawashima</dc:creator>
<dc:creator>Cristian G Beccaria</dc:creator>
<dc:creator>Federica Moalli</dc:creator>
<dc:creator>Bianca Partini</dc:creator>
<dc:creator>Valeria Fumagalli</dc:creator>
<dc:creator>Giulia Nosetto</dc:creator>
<dc:creator>Pietro Di Lucia</dc:creator>
<dc:creator>Ilaria Montali</dc:creator>
<dc:creator>José M Garcia-Manteiga</dc:creator>
<dc:creator>Elisa B Bono</dc:creator>
<dc:creator>Leonardo Giustini</dc:creator>
<dc:creator>Chiara Perucchini</dc:creator>
<dc:creator>Valentina Venzin</dc:creator>
<dc:creator>Serena Ranucci</dc:creator>
<dc:creator>Donato Inverso</dc:creator>
<dc:creator>Marco De Giovanni</dc:creator>
<dc:creator>Marco Genua</dc:creator>
<dc:creator>Renato Ostuni</dc:creator>
<dc:creator>Enrico Lugli</dc:creator>
<dc:creator>Masanori Isogawa</dc:creator>
<dc:creator>Carlo Ferrari</dc:creator>
<dc:creator>Carolina Boni</dc:creator>
<dc:creator>Paola Fisicaro</dc:creator>
<dc:creator>Luca G Guidotti</dc:creator>
<dc:creator>Matteo Iannacone</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Therapeutic potential of co-signaling receptor modulation in hepatitis B</dc:title>
<dc:identifier>pmid:38897196</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.038</dc:identifier>
</item>
<item>
<title>Ring-shaped odor coding in the antennal lobe of migratory locusts</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38897195/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>The representation of odors in the locust antennal lobe with its >;2,000 glomeruli has long remained a perplexing puzzle. We employed the CRISPR-Cas9 system to generate transgenic locusts expressing the genetically encoded calcium indicator GCaMP in olfactory sensory neurons. Using two-photon functional imaging, we mapped the spatial activation patterns representing a wide range of ecologically relevant odors across all six developmental stages. Our findings reveal a functionally ring-shaped...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 13:S0092-8674(24)00580-4. doi: 10.1016/j.cell.2024.05.036. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The representation of odors in the locust antennal lobe with its >;2,000 glomeruli has long remained a perplexing puzzle. We employed the CRISPR-Cas9 system to generate transgenic locusts expressing the genetically encoded calcium indicator GCaMP in olfactory sensory neurons. Using two-photon functional imaging, we mapped the spatial activation patterns representing a wide range of ecologically relevant odors across all six developmental stages. Our findings reveal a functionally ring-shaped organization of the antennal lobe composed of specific glomerular clusters. This configuration establishes an odor-specific chemotopic representation by encoding different chemical classes and ecologically distinct odors in the form of glomerular rings. The ring-shaped glomerular arrangement, which we confirm by selective targeting of OR70a-expressing sensory neurons, occurs throughout development, and the odor-coding pattern within the glomerular population is consistent across developmental stages. Mechanistically, this unconventional spatial olfactory code reflects the locust-specific and multiplexed glomerular innervation pattern of the antennal lobe.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38897195/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38897195</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.036>10.1016/j.cell.2024.05.036</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38897195</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Xingcong Jiang</dc:creator>
<dc:creator>Eleftherios Dimitriou</dc:creator>
<dc:creator>Veit Grabe</dc:creator>
<dc:creator>Ruo Sun</dc:creator>
<dc:creator>Hetan Chang</dc:creator>
<dc:creator>Yifu Zhang</dc:creator>
<dc:creator>Jonathan Gershenzon</dc:creator>
<dc:creator>Jürgen Rybak</dc:creator>
<dc:creator>Bill S Hansson</dc:creator>
<dc:creator>Silke Sachse</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Ring-shaped odor coding in the antennal lobe of migratory locusts</dc:title>
<dc:identifier>pmid:38897195</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.036</dc:identifier>
</item>
<item>
<title>Proximity-based labelling for proteomic mapping</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38898320/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 19. doi: 10.1038/s41569-024-01054-6. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38898320/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38898320</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01054-6>10.1038/s41569-024-01054-6</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38898320</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Zuzanna Jablonska</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Proximity-based labelling for proteomic mapping</dc:title>
<dc:identifier>pmid:38898320</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01054-6</dc:identifier>
</item>
<item>
<title>Suture-to-scan: ultrasonography-guided induction of heart injury</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38898319/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Jun 19. doi: 10.1038/s41569-024-01055-5. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38898319/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38898319</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01055-5>10.1038/s41569-024-01055-5</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38898319</guid>
<pubDate>Wed, 19 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Bronwyn Berkeley</dc:creator>
<dc:creator>Adrian Thomson</dc:creator>
<dc:date>2024-06-19</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Suture-to-scan: ultrasonography-guided induction of heart injury</dc:title>
<dc:identifier>pmid:38898319</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01055-5</dc:identifier>
</item>
<item>
<title>Perinatal depression and incident maternal cardiovascular disease: a neglected association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38889803/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 18:ehae340. doi: 10.1093/eurheartj/ehae340. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38889803/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38889803</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae340>10.1093/eurheartj/ehae340</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38889803</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Amani Meaidi</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Perinatal depression and incident maternal cardiovascular disease: a neglected association</dc:title>
<dc:identifier>pmid:38889803</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae340</dc:identifier>
</item>
<item>
<title>Perinatal depression and risk of maternal cardiovascular disease: a Swedish nationwide study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38889798/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Women with PND are at higher risk of CVD in middle adulthood. Reproductive history, including PND, should be considered in CVD risk assessments of women.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 18:ehae170. doi: 10.1093/eurheartj/ehae170. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Increasing evidence suggests that some reproductive factors/hazards are associated with a future risk of cardiovascular disease (CVD) in women. While major (non-perinatal) depression has consistently been associated with CVD, the long-term risk of CVD after perinatal depression (PND) is largely unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: A nationwide population-based matched cohort study involving 55 539 women diagnosed with PND during 2001-14 in Sweden and 545 567 unaffected women individually matched on age and year of conception/delivery was conducted. All women were followed up to 2020. Perinatal depression and CVD were identified from Swedish national health registers. Using multivariable Cox models, hazard ratios (HR) of any and type-specific CVD according to PND were estimated.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The mean age at the PND diagnosis was 30.8 [standard deviation (SD) 5.6] years. During the follow-up of up to 20 years (mean 10.4, SD 3.6), 3533 (6.4%) women with PND (expected number 2077) and 20 202 (3.7%) unaffected women developed CVD. Compared with matched unaffected women, women with PND had a 36% higher risk of developing CVD [adjusted HR = 1.36, 95% confidence interval (CI): 1.31-1.42], while compared with their sisters, women with PND had a 20% higher risk of CVD (adjusted HR = 1.20, 95% CI 1.07-1.34). The results were most pronounced in women without a history of psychiatric disorder (P for interaction &lt; .001). The association was observed for all CVD subtypes, with the highest HR in the case of hypertensive disease (HR = 1.50, 95% CI: 1.41-1.60), ischaemic heart disease (HR = 1.37, 95% CI: 1.13-1.65), and heart failure (HR 1.36, 95% CI: 1.06-1.74).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Women with PND are at higher risk of CVD in middle adulthood. Reproductive history, including PND, should be considered in CVD risk assessments of women.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38889798/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38889798</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae170>10.1093/eurheartj/ehae170</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38889798</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Donghao Lu</dc:creator>
<dc:creator>Unnur A Valdimarsdóttir</dc:creator>
<dc:creator>Dang Wei</dc:creator>
<dc:creator>Yufeng Chen</dc:creator>
<dc:creator>Ole A Andreassen</dc:creator>
<dc:creator>Fang Fang</dc:creator>
<dc:creator>Krisztina D László</dc:creator>
<dc:creator>Emma Bränn</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Perinatal depression and risk of maternal cardiovascular disease: a Swedish nationwide study</dc:title>
<dc:identifier>pmid:38889798</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae170</dc:identifier>
</item>
<item>
<title>The genomic and cellular basis of biosynthetic innovation in rove beetles</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38889727/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240620021300&amp;v=2.18.0.post9+e462414
      <description>How evolution at the cellular level potentiates macroevolutionary change is central to understanding biological diversification. The >;66,000 rove beetle species (Staphylinidae) form the largest metazoan family. Combining genomic and cell type transcriptomic insights spanning the largest clade, Aleocharinae, we retrace evolution of two cell types comprising a defensive gland-a putative catalyst behind staphylinid megadiversity. We identify molecular evolutionary steps leading to benzoquinone...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 11:S0092-8674(24)00521-X. doi: 10.1016/j.cell.2024.05.012. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">How evolution at the cellular level potentiates macroevolutionary change is central to understanding biological diversification. The >;66,000 rove beetle species (Staphylinidae) form the largest metazoan family. Combining genomic and cell type transcriptomic insights spanning the largest clade, Aleocharinae, we retrace evolution of two cell types comprising a defensive gland-a putative catalyst behind staphylinid megadiversity. We identify molecular evolutionary steps leading to benzoquinone production by one cell type via a mechanism convergent with plant toxin release systems, and synthesis by the second cell type of a solvent that weaponizes the total secretion. This cooperative system has been conserved since the Early Cretaceous as Aleocharinae radiated into tens of thousands of lineages. Reprogramming each cell type yielded biochemical novelties enabling ecological specialization-most dramatically in symbionts that infiltrate social insect colonies via host-manipulating secretions. Our findings uncover cell type evolutionary processes underlying the origin and evolvability of a beetle chemical innovation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38889727/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240620021300&v=2.18.0.post9+e462414">38889727</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.012>10.1016/j.cell.2024.05.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38889727</guid>
<pubDate>Tue, 18 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Sheila A Kitchen</dc:creator>
<dc:creator>Thomas H Naragon</dc:creator>
<dc:creator>Adrian Brückner</dc:creator>
<dc:creator>Mark S Ladinsky</dc:creator>
<dc:creator>Sofia A Quinodoz</dc:creator>
<dc:creator>Jean M Badroos</dc:creator>
<dc:creator>Joani W Viliunas</dc:creator>
<dc:creator>Yuriko Kishi</dc:creator>
<dc:creator>Julian M Wagner</dc:creator>
<dc:creator>David R Miller</dc:creator>
<dc:creator>Mina Yousefelahiyeh</dc:creator>
<dc:creator>Igor A Antoshechkin</dc:creator>
<dc:creator>K Taro Eldredge</dc:creator>
<dc:creator>Stacy Pirro</dc:creator>
<dc:creator>Mitchell Guttman</dc:creator>
<dc:creator>Steven R Davis</dc:creator>
<dc:creator>Matthew L Aardema</dc:creator>
<dc:creator>Joseph Parker</dc:creator>
<dc:date>2024-06-18</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The genomic and cellular basis of biosynthetic innovation in rove beetles</dc:title>
<dc:identifier>pmid:38889727</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.012</dc:identifier>
</item>





























</channel>
</rss>